Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018).Article
CAS
PubMed
Google Scholar
Petzold, A. The 2022 Lady Estelle Wolfson lectureship on neurofilaments. J. Neurochem. 163, 179–219 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Norgren, N., Karlsson, J.-E., Rosengren, L. & Stigbrand, T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid. Hybridomics 21, 53–59 (2002).Article
CAS
PubMed
Google Scholar
Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Gisslén, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135–140 (2016).Article
PubMed
Google Scholar
Spitzenberger, F. et al. Laboratory-developed tests: design of a regulatory strategy in compliance with the international state-of-the-art and the regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]). Ther. Innov. Regul. Sci. 56, 47–64 (2022).Article
PubMed
Google Scholar
Hauser, S. L. et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383, 546–557 (2020).Article
CAS
PubMed
Google Scholar
Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316 (2019).Article
CAS
PubMed
Google Scholar
Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099–1110 (2022).Article
CAS
PubMed
Google Scholar
Mullard, A. NfL makes regulatory debut as neurodegenerative disease biomarker. Nat. Rev. Drug Discov. 22, 431–434 (2023).Article
CAS
PubMed
Google Scholar
Biogen. FDA Grants Accelerated Approval for QALSODYTM (Tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-qalsodytm-tofersen-sod1-als (2023).Leptak, C. & Kozauer, N. Letter of Support to the International Progressive Multiple Sclerosis Alliance. U.S. Food & Drug Administration https://www.fda.gov/media/149608/download (2021).Cooke, E. Letter of Support of Neurofilament Light in Childhood Neurological Diseases. European Medicines Agency https://www.ema.europa.eu/en/documents/other/letter-support-neurofilament-light-childhood-neurological-diseases_en.pdf (2022).Koini, M. et al. Factors influencing serum neurofilament light chain levels in normal aging. Aging 13, 25729–25738 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Fitzgerald, K. C. et al. Contributors to serum NfL levels in people without neurologic disease. Ann. Neurol. 92, 688–698 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246–257 (2022).Article
PubMed
Google Scholar
Shaw, G. et al. Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration. Brain Commun. 5, fcad067 (2023).Article
PubMed
PubMed Central
Google Scholar
Gafson, A. R. et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 143, 1975–1998 (2020).Article
PubMed
PubMed Central
Google Scholar
Andreasson, U. et al. Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood. Clin. Chem. Lab. Med. 61, 1245–1254 (2023).Article
CAS
PubMed
Google Scholar
Eldirany, S. A., Lomakin, I. B., Ho, M. & Bunick, C. G. Recent insight into intermediate filament structure. Curr. Opin. Cell Biol. 68, 132–143 (2021).Article
CAS
PubMed
Google Scholar
Ghosh, K., Huihui, J., Phillips, M. & Haider, A. Rules of physical mathematics govern intrinsically disordered proteins. Annu. Rev. Biophys. 51, 355–376 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Janmey, P. A., Leterrier, J.-F. & Herrmann, H. Assembly and structure of neurofilaments. Curr. Opin. Colloid Interface Sci. 8, 40–47 (2003).Article
CAS
Google Scholar
Trimpin, S. et al. Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. Biochemistry 43, 2091–2105 (2004).Article
CAS
PubMed
Google Scholar
Petzold, A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233, 183–198 (2005).Article
CAS
PubMed
Google Scholar
Rebelo, A. P. et al. Cryptic amyloidogenic elements in the 3’ UTRs of neurofilament genes trigger axonal neuropathy. Am. J. Hum. Genet. 98, 597–614 (2016).Article
CAS
PubMed
PubMed Central
Google Scholar
Murray, K. A. et al. Identifying amyloid-related diseases by mapping mutations in low-complexity protein domains to pathologies. Nat. Struct. Mol. Biol. 29, 529–536 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Xiao, S., McLean, J. & Robertson, J. Neuronal intermediate filaments and ALS: a new look at an old question. Biochim. Biophys. Acta Mol. Basis Dis. 1762, 1001–1012 (2006).Article
CAS
Google Scholar
Petzold, A. et al. Protein aggregate formation permits millennium-old brain preservation. J. R. Soc. Interface 17, 20190775 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Briot, J., Simon, M. & Méchin, M.-C. Deimination, intermediate filaments and associated proteins. Int. J. Mol. Sci. 21, 8746 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Cloos, P. A. C. & Christgau, S. Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity. Biogerontology 5, 139–158 (2004).Article
CAS
PubMed
Google Scholar
Yuzwa, S. A. et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 8, 393–399 (2012).Article
CAS
PubMed
Google Scholar
Zucchi, E. et al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J. Neurochem. 146, 631–641 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Jones, J. B. & Safinya, C. R. Interplay between liquid crystalline and isotropic gels in self-assembled neurofilament networks. Biophys. J. 95, 823–835 (2008).Article
CAS
PubMed
PubMed Central
Google Scholar
Lasek, R. J., Phillips, L., Katz, M. J. & Autilio-Gambetti, L. Function and evolution of neurofilament proteins. Ann. N. Y. Acad. Sci. 455, 462–478 (1985).Article
CAS
PubMed
Google Scholar
Monaco, S., Autilio-Gambetti, L., Lasek, R. J., Katz, M. J. & Gambetti, P. Experimental increase of neurofilament transport rate: decreases in neurofilament number and in axon diameter. J. Neuropathol. Exp. Neurol. 48, 23–32 (1989).Article
CAS
PubMed
Google Scholar
Lasek, R. J., Oblinger, M. M. & Drake, P. F. Molecular biology of neuronal geometry: expression of neurofilament genes influences axonal diameter. Cold Spring Harb. Symp. Quant. Biol. 48, 731–744 (1983).Article
CAS
PubMed
Google Scholar
Balaratnasingam, C. et al. Axonal transport and cytoskeletal changes in the laminar regions after elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. 48, 3632–3644 (2007).Article
PubMed
Google Scholar
Vial, J. D. The early changes in the axoplasm during Wallerian degeneration. J. Biophys. Biochem. Cytol. 4, 551–555 (1958).Article
CAS
PubMed
PubMed Central
Google Scholar
Lasek, R. J. Bidirectional transport of radioactively labelled axoplasmic components. Nature 216, 1212–1214 (1967).Article
CAS
PubMed
Google Scholar
Nixon, R. A. & Logvinenko, K. B. Multiple fates of newly synthesized neurofilament proteins: evidence for a stationary neurofilament network distributed nonuniformly along axons of retinal ganglion cell neurons. J. Cell Biol. 102, 647–659 (1986).Article
CAS
PubMed
Google Scholar
Mutalik, S. P. & Ghose, A. Axonal cytomechanics in neuronal development. J. Biosci. 45, 64 (2020).Article
PubMed
Google Scholar
Gentil, B. J. et al. Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease. FASEB J. 26, 1194–1203 (2012).Article
CAS
PubMed
Google Scholar
Wagner, O. I. et al. Mechanisms of mitochondria-neurofilament interactions. J. Neurosci. 23, 9046–9058 (2003).Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu, P.-P. et al. Transverse endoplasmic reticulum expansion in hereditary spastic paraplegia corticospinal axons. Hum. Mol. Genet. 31, 2779–2795 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Dashiell, S. M., Tanner, S. L., Pant, H. C. & Quarles, R. H. Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases. J. Neurochem. 81, 1263–1272 (2002).Article
CAS
PubMed
Google Scholar
Petzold, A. et al. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain 134, 464–483 (2011).Article
PubMed
PubMed Central
Google Scholar
Altmann, P. et al. Seven day pre-analytical stability of serum and plasma neurofilament light chain. Sci. Rep. 11, 11034 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Brureau, A. et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol. Dis. 104, 73–84 (2017).Article
CAS
PubMed
Google Scholar
Geisler, N. & Weber, K. Comparison of the proteins of two immunologically distinct intermediate-sized filaments by amino acid sequence analysis: desmin and vimentin. Proc. Natl Acad. Sci. USA 78, 4120–4123 (1981).Article
CAS
PubMed
PubMed Central
Google Scholar
Budelier, M. M. et al. A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease. Brain Commun. 4, fcac045 (2022).Article
PubMed
PubMed Central
Google Scholar
Woltsche, N. et al. Neurofilament light chain: a new marker for neuronal decay in the anterior chamber fluid of patients with glaucoma. Br. J. Ophthalmol. 107, 1432–1437 (2022).Article
PubMed
Google Scholar
Plog, B. A. et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J. Neurosci. 35, 518–526 (2015).Article
PubMed
PubMed Central
Google Scholar
Engel, S. et al. Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension. Fluids Barriers CNS 20, 3 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Hier, D. B. et al. Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. Biomark. Res. 9, 70 (2021).Article
PubMed
PubMed Central
Google Scholar
Azizi, S. et al. A kinetic model for blood biomarker levels after mild traumatic brain injury. Front. Neurol. 12, 668606 (2021).Article
PubMed
PubMed Central
Google Scholar
Thelin, E. P. et al. Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front. Neurol. 8, 300 (2017).Article
PubMed
PubMed Central
Google Scholar
Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Keddie, S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 146, 4562–4573 (2023).Article
PubMed
PubMed Central
Google Scholar
Yuan, A. et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J. Neurosci. 32, 8501–8508 (2012).Article
CAS
PubMed
PubMed Central
Google Scholar
Petzold, A., Keir, G., Green, A. J. E., Giovannoni, G. & Thompson, E. J. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J. Immunol. Methods 278, 179–190 (2003).Article
CAS
PubMed
Google Scholar
Gaiottino, J. et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8, e75091 (2013).Article
CAS
PubMed
PubMed Central
Google Scholar
Rissin, D. M. & Walt, D. R. Digital concentration readout of single enzyme molecules using femtoliter arrays and Poisson statistics. Nano Lett. 6, 520–523 (2006).Article
CAS
PubMed
Google Scholar
Wilson, D. H. et al. The simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J. Lab. Autom. 21, 533–547 (2016).Article
CAS
PubMed
Google Scholar
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599 (2010).Article
CAS
PubMed
PubMed Central
Google Scholar
Petzold, A. et al. Neurofilament ELISA validation. J. Immunol. Methods 352, 23–31 (2010).Article
CAS
PubMed
Google Scholar
Kuhle, J. et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655–1661 (2016).Article
CAS
PubMed
Google Scholar
Brousse, M. et al. Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis. Eur. J. Neurol. 30, 1919–1927 (2023).Article
PubMed
Google Scholar
Lee, S. et al. Development of a highly sensitive neurofilament light chain assay on an automated immunoassay platform. Front. Neurol. 13, 935382 (2022).Article
PubMed
PubMed Central
Google Scholar
Yuan, A. & Nixon, R. A. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front. Neurosci. 15, 689938 (2021).Article
PubMed
PubMed Central
Google Scholar
Harp, C. et al. Development of an age-adjusted model for blood neurofilament light chain. Ann. Clin. Transl. Neurol. 9, 444–453 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Khalil, M. et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun. 11, 812 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Yilmaz, A. et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev. Mol. Diagn. 17, 761–770 (2017).Article
CAS
PubMed
Google Scholar
Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035–1048 (2019).Article
PubMed
PubMed Central
Google Scholar
Idland, A.-V. et al. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol. Aging 49, 138–144 (2017).Article
CAS
PubMed
Google Scholar
Reiber, H. Flow rate of cerebrospinal fluid (CSF) — a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 122, 189–203 (1994).Article
CAS
PubMed
Google Scholar
Mattsson, N., Andreasson, U., Zetterberg, H. & Blennow, K., Alzheimer’s Disease Neuroimaging Initiative.Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557–566 (2017).Article
PubMed
PubMed Central
Google Scholar
Manouchehrinia, A. et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann. Clin. Transl. Neurol. 7, 139–143 (2020).Article
PubMed
PubMed Central
Google Scholar
Simrén, J. et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years. Brain Commun. 4, fcac174 (2022).Article
PubMed
PubMed Central
Google Scholar
Tang, R. et al. Association of neurofilament light chain with renal function: mechanisms and clinical implications. Alzheimers Res. Ther. 14, 189 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Akamine, S. et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci. Rep. 10, 20350 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Kosa, P. et al. Enhancing the clinical value of serum neurofilament light chain measurement. JCI Insight 7, e161415 (2022).Article
PubMed
PubMed Central
Google Scholar
Simonsen, A. H. et al. Neurofilament light chain levels in serum among a large mixed memory clinic cohort: confounders and diagnostic usefulness. Alzheimers Dement. 15, e12512 (2023).
Google Scholar
Sjölin, K. et al. Serum neurofilament light chain in patients with atrial fibrillation. J. Am. Heart Assoc. 11, e025910 (2022).Article
PubMed
PubMed Central
Google Scholar
Polymeris, A. A. et al. Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Commun. 2, fcaa166 (2020).Article
PubMed
PubMed Central
Google Scholar
Li, Y. et al. Neurofilament light chain is a promising biomarker in alcohol dependence. Front. Psychiatry 12, 754969 (2021).Article
PubMed
PubMed Central
Google Scholar
Sareban, M. et al. Serum neurofilament level increases after ascent to 4559 m but is not related to acute mountain sickness. Eur. J. Neurol. 28, 1004–1008 (2021).Article
PubMed
Google Scholar
Sönksen, S.-E. et al. Brain structure and neurocognitive function in two professional mountaineers during 35 days of severe normobaric hypoxia. Eur. J. Neurol. 29, 3112–3116 (2022).Article
PubMed
Google Scholar
Isung, J. et al. Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects. Sci. Rep. 11, 1669 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Joisten, N. et al. Exercise diminishes plasma neurofilament light chain and reroutes the kynurenine pathway in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 8, e982 (2021).Article
PubMed
PubMed Central
Google Scholar
Bazarian, J. J. et al. Effects of physical exertion on early changes in blood-based brain biomarkers: implications for the acute point of care diagnosis of concussion. J. Neurotrauma 40, 693–705 (2023).Article
PubMed
PubMed Central
Google Scholar
Kuhle, J. et al. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult. Scler. 28, 573–582 (2022).Article
CAS
PubMed
Google Scholar
Sormani, M. P. et al. Blood neurofilament light as a potential endpoint in phase 2 studies in MS. Ann. Clin. Transl. Neurol. 6, 1081–1089 (2019).Article
PubMed
PubMed Central
Google Scholar
Leppert, D. et al. Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials. Neurology 98, e2120–e2131 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Vermunt, L. et al. Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface. Ann. Clin. Transl. Neurol. 9, 1832–1837 (2022).Article
PubMed
PubMed Central
Google Scholar
Bornhorst, J. A. et al. Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort. Clin. Chim. Acta 535, 153–156 (2022).Article
CAS
PubMed
Google Scholar
Borghi, E. et al. Construction of the World Health Organization child growth standards: selection of methods for attained growth curves. Stat. Med. 25, 247–265 (2006).Article
CAS
PubMed
Google Scholar
Abdelhak, A. et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 22, 826–833 (2023).Article
CAS
PubMed
Google Scholar
Wilson, D. et al. Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury. Clin. Chem. Lab. Med. 62, 322–331 (2023).Article
PubMed
Google Scholar
Janiaud, P. et al. Personalized treatment decision algorithms for the clinical implementation of serum neurofilament light chain in multiple sclerosis: a modified Delphi study. Mult. Scler. J. 29, 650–1044 (2023).
Google Scholar
Lycke, J. N., Karlsson, J. E., Andersen, O. & Rosengren, L. E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64, 402–404 (1998).Article
CAS
PubMed
PubMed Central
Google Scholar
Rosengren, L. E., Karlsson, J. E., Karlsson, J. O., Persson, L. I. & Wikkelsø, C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 67, 2013–2018 (1996).Article
CAS
PubMed
Google Scholar
Delcoigne, B. et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94, e1201–e1212 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92, e1007–e1015 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Bittner, S. et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine 56, 102807 (2020).Article
PubMed
PubMed Central
Google Scholar
Piehl, F. et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult. Scler. 24, 1046–1054 (2018).Article
CAS
PubMed
Google Scholar
Ziemssen, T. et al. Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials. Front. Immunol. 13, 852563 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Bar-Or, A. et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine 93, 104662 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Kapoor, R. et al. Natalizumab reduces serum concentrations of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study (S12.008). Neurology 92, https://doi.org/10.1212/WNL.92.15_supplement.S12.008 (2019).Kuhle, J. et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88, 826–831 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Røsjø, E. et al. Natural variation of vitamin D and neurofilament light chain in relapsing-remitting multiple sclerosis. Front. Neurol. 11, 329 (2020).Article
PubMed
PubMed Central
Google Scholar
Smolders, J. et al. Vitamin D 3 supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol. Scand. 141, 77–80 (2020).Article
CAS
PubMed
Google Scholar
Bridel, C. et al. Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis. Neurology 97, e1898–e1905 (2021).Article
CAS
PubMed
Google Scholar
Barro, C. et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141, 2382–2391 (2018).Article
PubMed
Google Scholar
Chitnis, T. et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann. Clin. Transl. Neurol. 5, 1478–1491 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Cantó, E. et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 76, 1359 (2019).Article
PubMed
PubMed Central
Google Scholar
Thebault, S. et al. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci. Rep. 10, 10381 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Thebault, S. et al. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol. Neuroimmunol. Neuroinflamm. 6, e598 (2019).Article
PubMed
PubMed Central
Google Scholar
Buchmann, A. et al. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Eur. J. Neurol. 30, 1389–1399 (2023).Article
PubMed
Google Scholar
Lie, I. A. et al. Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. J. Neurol. Neurosurg. Psychiatry 93, 849–857 (2022).Article
PubMed
Google Scholar
Maggi, P. et al. Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurology 97, e543–e553 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Abdelhak, A. et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol. 80, 1317–1325 (2023).Article
PubMed
Google Scholar
Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287–297 (2023).Article
PubMed
PubMed Central
Google Scholar
Voigt, I., Inojosa, H., Wenk, J., Akgün, K. & Ziemssen, T. Building a monitoring matrix for the management of multiple sclerosis. Autoimmun. Rev. 22, 103358 (2023).Article
PubMed
Google Scholar
Miyazawa, I. et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 68, 865–867 (2007).Article
CAS
PubMed
Google Scholar
Mariotto, S. et al. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J. Neurol. Neurosurg. Psychiatry 90, 1293–1296 (2019).Article
PubMed
Google Scholar
Mariotto, S. et al. Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult. Scler. J. Exp. Transl. Clin. 3, 205521731774309 (2017).
Google Scholar
Watanabe, M. et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93, e1299–e1311 (2019).Article
CAS
PubMed
Google Scholar
Chang, X. et al. Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front. Immunol. 12, 647618 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Kim, H. et al. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult. Scler. 28, 512–521 (2022).Article
CAS
PubMed
Google Scholar
Kim, H. et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol. Neuroimmunol. Neuroinflamm. 7, e708 (2020).Article
PubMed
PubMed Central
Google Scholar
Lista, S. et al. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer’s disease. Neurochem. Int. 108, 355–360 (2017).Article
CAS
PubMed
Google Scholar
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).Article
PubMed
PubMed Central
Google Scholar
Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Dhiman, K. et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer’s disease. Alzheimers Dement. 12, e12005 (2020).
Google Scholar
Verberk, I. M. W. et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res. Ther. 12, 118 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Moore, E. E. et al. Neurofilament relates to white matter microstructure in older adults. Neurobiol. Aging 70, 233–241 (2018).Article
PubMed
PubMed Central
Google Scholar
Meeker, K. L. et al. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiol. Dis. 166, 105662 (2022).Article
PubMed
PubMed Central
Google Scholar
Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870–881 (2019).Article
PubMed
Google Scholar
Benussi, A. et al. Diagnostic and prognostic value of serum NfL and p-Tau 181 in frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 91, 960–967 (2020).Article
PubMed
Google Scholar
Steinacker, P. et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci. Rep. 6, 38737 (2016).Article
CAS
PubMed
PubMed Central
Google Scholar
Abu-Rumeileh, S. et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res. Ther. 10, 3 (2018).Article
PubMed
PubMed Central
Google Scholar
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Lleó, A. et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 15, 742–753 (2019).Article
PubMed
Google Scholar
Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60–67 (2016).Article
PubMed
PubMed Central
Google Scholar
Fortea, J. et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 17, 860–869 (2018).Article
CAS
PubMed
Google Scholar
Aamodt, W. W. et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov. Disord. 36, 2945–2950 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Bäckström, D. C. et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 72, 1175–1182 (2015).Article
PubMed
Google Scholar
Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930–937 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Koga, S., Sekiya, H., Kondru, N., Ross, O. A. & Dickson, D. W. Neuropathology and molecular diagnosis of synucleinopathies. Mol. Neurodegener. 16, 83 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Thijssen, E. H. et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimers Dement. 14, e12285 (2022).
Google Scholar
Baiardi, S. et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res. Ther. 14, 153 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J. Neurol. Neurosurg. Psychiatry 57, 416–418 (1994).Article
Google Scholar
Grossman, M. et al. Frontotemporal lobar degeneration. Nat. Rev. Dis. Prim. 9, 40 (2023).Article
PubMed
Google Scholar
Forgrave, L. M., Ma, M., Best, J. R. & DeMarco, M. L. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement. 11, 730–743 (2019).
Google Scholar
Davy, V., Dumurgier, J., Fayosse, A., Paquet, C. & Cognat, E. Neurofilaments as emerging biomarkers of neuroaxonal damage to differentiate behavioral frontotemporal dementia from primary psychiatric disorders: a systematic review. Diagnostics 11, 754 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Al Shweiki, M. R. et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J. Psychiatr. Res. 113, 137–140 (2019).Article
PubMed
Google Scholar
Ducharme, S. et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 143, 1632–1650 (2020).Article
PubMed
PubMed Central
Google Scholar
Willemse, E. A. J., Scheltens, P., Teunissen, C. E. & Vijverberg, E. G. B. A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimers Res. Ther. 13, 101 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Gendron, T. F. et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep. Med. 3, 100607 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Staffaroni, A. M. et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat. Med. 28, 2194–2206 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Giannini, L. A. A. et al. Clinical value of longitudinal serum neurofilament light chain in prodromal genetic frontotemporal dementia. Neurology 101, e1069–e1082 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Brettschneider, J., Petzold, A., Süssmuth, S. D., Ludolph, A. C. & Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66, 852–856 (2006).Article
CAS
PubMed
Google Scholar
Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. & Andersen, P. M. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol. 14, 1329–1333 (2007).Article
CAS
PubMed
Google Scholar
Lu, C.-H. et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247–2257 (2015).Article
CAS
PubMed
PubMed Central
Google Scholar
Menke, R. A. L. et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann. Clin. Transl. Neurol. 2, 748–755 (2015).Article
CAS
PubMed
PubMed Central
Google Scholar
Steinacker, P. et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry 87, 12–20 (2016).PubMed
Google Scholar
Steinacker, P. et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 112–119 (2017).Article
CAS
PubMed
Google Scholar
De Schaepdryver, M. et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 89, 367–373 (2018).Article
PubMed
Google Scholar
Schreiber, S. et al. Significance of CSF NfL and tau in ALS. J. Neurol. 265, 2633–2645 (2018).Article
CAS
PubMed
Google Scholar
Abu-Rumeileh, S. et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 267, 1699–1708 (2020).Article
CAS
PubMed
Google Scholar
Halbgebauer, S. et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J. Neurol. Neurosurg. Psychiatry 93, 68–74 (2022).Article
PubMed
Google Scholar
Verde, F. et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 157–164 (2019).Article
PubMed
Google Scholar
Meyer, T. et al. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study. Eur. J. Neurol. 30, 1600–1610 (2023).Article
PubMed
Google Scholar
Abu-Rumeileh, S. et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J. Neurol. Neurosurg. Psychiatry 91, 1181–1188 (2020).Article
PubMed
Google Scholar
Halbgebauer, S. et al. Blood β-synuclein and neurofilament light chain during the course of prion disease. Neurology 98, e1434–e1445 (2022).Article
CAS
PubMed
Google Scholar
Gille, B. et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 45, 291–304 (2019).Article
CAS
PubMed
Google Scholar
Poesen, K. et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88, 2302–2309 (2017).Article
CAS
PubMed
Google Scholar
Oeckl, P. et al. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 139, 119–134 (2020).Article
CAS
PubMed
Google Scholar
Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V. & Malaspina, A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84, 130–139 (2018).Article
CAS
PubMed
Google Scholar
Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59–e69 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Thompson, A. G. et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 4, fcac029 (2022).Article
PubMed
PubMed Central
Google Scholar
Feneberg, E. et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90, e22–e30 (2018).Article
CAS
PubMed
Google Scholar
De Schaepdryver, M. et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann. Clin. Transl. Neurol. 6, 1971–1979 (2019).Article
PubMed
PubMed Central
Google Scholar
Bjornevik, K. et al. Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 97, e1466–e1474 (2021).Article
PubMed
PubMed Central
Google Scholar
Benatar, M. et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Frontotemporal Degener. 20, 538–548 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Weydt, P. et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 79, 152–158 (2016).Article
CAS
PubMed
Google Scholar
Goutman, S. A. et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 21, 480–493 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Boylan, K. B. et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 467–472 (2013).Article
PubMed
Google Scholar
Gendron, T. F. et al. Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 82, 139–146 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Su, W.-M. et al. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta-analysis. EBioMedicine 74, 103732 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Devos, D. et al. A ferroptosis-based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci. Rep. 9, 2918 (2019).Article
PubMed
PubMed Central
Google Scholar
Shefner, J. M. et al. Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol. 79, 1312–1318 (2022).Article
PubMed
Google Scholar
Witzel, S. et al. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl. Neurodegener. 10, 31 (2021).Article
PubMed
PubMed Central
Google Scholar
Miller, T. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109–119 (2020).Article
CAS
PubMed
Google Scholar
Meyer, T. et al. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice. Muscle Nerve 67, 515–521 (2023).Article
CAS
PubMed
Google Scholar
Benatar, M. et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19, 1248–1258 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Esselin, F. et al. Repeated neurofilament light chain measurements did not capture riluzole therapeutic effect in amyotrophic lateral sclerosis patients. CNS Neurosci. Ther. 28, 1532–1538 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Shefner, J. M. et al. A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 131, 1975–1978 (2020).Article
PubMed
Google Scholar
The German Neurological Society (DGN). Guidelines motoneuron diseases. dgn.org, https://dgn.org/leitlinie/motoneuronerkrankungen [in German] (2021).Gattringer, T. et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 89, 2108–2114 (2017).Article
PubMed
PubMed Central
Google Scholar
Tiedt, S. et al. Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology 91, e1338–e1347 (2018).Article
CAS
PubMed
Google Scholar
Pedersen, A. et al. Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. J. Neurol. 266, 2796–2806 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Gendron, T. F. et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci. Transl. Med. 12, eaay1913 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Sanchez, J. D. et al. Temporal patterning of neurofilament light as a blood-based biomarker for stroke: a systematic review and meta-analysis. Front. Neurol. 13, 841898 (2022).Article
PubMed
PubMed Central
Google Scholar
De Marchis, G. M. et al. Serum neurofilament light chain in patients with acute cerebrovascular events. Eur. J. Neurol. 25, 562–568 (2018).Article
PubMed
Google Scholar
Onatsu, J. et al. Serum neurofilament light chain concentration correlates with infarct volume but not prognosis in acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 28, 2242–2249 (2019).Article
PubMed
Google Scholar
Traenka, C. et al. Serum neurofilament light chain levels are associated with clinical characteristics and outcome in patients with cervical artery dissection. Cerebrovasc. Dis. 40, 222–227 (2015).Article
PubMed
Google Scholar
Pujol-Calderón, F. et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci. Lett. 698, 58–63 (2019).Article
PubMed
Google Scholar
Uphaus, T. et al. NfL (neurofilament light chain) levels as a predictive marker for long-term outcome after ischemic stroke. Stroke 50, 3077–3084 (2019).Article
CAS
PubMed
Google Scholar
Wang, P., Fan, J., Yuan, L., Nan, Y. & Nan, S. Serum neurofilament light predicts severity and prognosis in patients with ischemic stroke. Neurotox. Res. 37, 987–995 (2020).Article
CAS
PubMed
Google Scholar
Rahmig, J. et al. Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion. J. Neurol. Sci. 429, 118063 (2021).Article
CAS
PubMed
Google Scholar
Jacob, M. A. et al. Increased neurofilament light chain is associated with increased risk of long-term mortality in cerebral small vessel disease. J. Stroke 24, 296–299 (2022).Article
PubMed
PubMed Central
Google Scholar
Duering, M. et al. Serum neurofilament light chain levels are related to small vessel disease burden. J. Stroke 20, 228–238 (2018).Article
PubMed
PubMed Central
Google Scholar
Peters, N. et al. Serum neurofilament light chain is associated with incident lacunes in progressive cerebral small vessel disease. J. Stroke 22, 369–376 (2020).Article
PubMed
PubMed Central
Google Scholar
Peters, N. Neurofilament light chain as a biomarker in cerebral small-vessel disease. Mol. Diagn. Ther. 26, 1–6 (2022).Article
PubMed
Google Scholar
Gravesteijn, G. et al. Serum neurofilament light correlates with CADASIL disease severity and survival. Ann. Clin. Transl. Neurol. 6, 46–56 (2019).Article
CAS
PubMed
Google Scholar
Chen, C.-H., Cheng, Y.-W., Chen, Y.-F., Tang, S.-C. & Jeng, J.-S. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL. J. Neuroinflammation 17, 124 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang, X., Wang, H., Li, L., Deng, X. & Bo, L. Neurofilament light chain: a candidate biomarker of perioperative stroke. Front. Aging Neurosci. 14, 921809 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Taylor, J. et al. Perioperative ischaemic brain injury and plasma neurofilament light: a secondary analysis of two prospective cohort studies. Br. J. Anaesth. 130, e361–e369 (2023).Article
PubMed
Google Scholar
Pinter, D. et al. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J. Cereb. Blood Flow. Metab. 39, 1669–1677 (2019).Article
PubMed
Google Scholar
Egle, M. et al. Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. J. Neurol. Neurosurg. Psychiatry 92, 582–589 (2021).Article
PubMed
Google Scholar
Heshmatollah, A. et al. Plasma β-amyloid, total-tau, and neurofilament light chain levels and the risk of stroke: a prospective population-based study. Neurology 98, e1729–e1737 (2022).Article
CAS
PubMed
Google Scholar
Korley, F. K. et al. Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus. Stroke 50, 1669–1675 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Polymeris, A. A. et al. Renal function and body mass index contribute to serum neurofilament light chain levels in elderly patients with atrial fibrillation. Front. Neurosci. 16, 819010 (2022).Article
PubMed
PubMed Central
Google Scholar
Lota, K. S. et al. Rotational head acceleration and traumatic brain injury in combat sports: a systematic review. Br. Med. Bull. 141, 33–46 (2022).Article
PubMed
PubMed Central
Google Scholar
Bergman, J. et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).Article
PubMed
PubMed Central
Google Scholar
Shahim, P. et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci. Rep. 6, 36791 (2016).Article
CAS
PubMed
PubMed Central
Google Scholar
Gill, J. et al. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI. Neurology 91, e1385–e1389 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Iverson, G. L. et al. Serum neurofilament light is elevated differentially in older adults with uncomplicated mild traumatic brain injuries. J. Neurotrauma 36, 2400–2406 (2019).Article
PubMed
Google Scholar
Hossain, I. et al. Early levels of glial fibrillary acidic protein and neurofilament light protein in predicting the outcome of mild traumatic brain injury. J. Neurotrauma 36, 1551–1560 (2019).Article
PubMed
Google Scholar
Shahim, P. et al. Neurofilament light as a biomarker in traumatic brain injury. Neurology 95, e610–e622 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Shahim, P., Tegner, Y., Marklund, N., Blennow, K. & Zetterberg, H. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology 90, e1780–e1788 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Shahim, P., Zetterberg, H., Tegner, Y. & Blennow, K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788–1794 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Farragher, C. D., Ku, Y. & Powers, J. E. The potential role of neurofilament light in mild traumatic brain injury diagnosis: a systematic review. Cureus 14, e31301 (2022).PubMed
PubMed Central
Google Scholar
Thelin, E. et al. A serum protein biomarker panel improves outcome prediction in human traumatic brain injury. J. Neurotrauma 36, 2850–2862 (2019).Article
PubMed
PubMed Central
Google Scholar
Barro, C., Chitnis, T. & Weiner, H. L. Blood neurofilament light: a critical review of its application to neurologic disease. Ann. Clin. Transl. Neurol. 7, 2508–2523 (2020).Article
PubMed
PubMed Central
Google Scholar
Rosén, H., Karlsson, J.-E. & Rosengren, L. CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J. Neurological Sci. 221, 19–24 (2004).Article
Google Scholar
Rana, O. R. et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int. J. Cardiol. 168, 1322–1327 (2013).Article
PubMed
Google Scholar
Rosén, C. et al. Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation 85, 227–232 (2014).Article
PubMed
Google Scholar
Rundgren, M., Friberg, H., Cronberg, T., Romner, B. & Petzold, A. Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest. Crit. Care 16, R45 (2012).Article
PubMed
PubMed Central
Google Scholar
Abu-Rumeileh, S. et al. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146, 421–427 (2022).Article
Google Scholar
Moseby-Knappe, M. et al. Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol. 76, 64 (2019).Article
PubMed
Google Scholar
Disanto, G. et al. Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. Epilepsy Behav. 101, 106432 (2019).Article
PubMed
Google Scholar
Fisse, A. L. et al. Serum neurofilament light chain as outcome marker for intensive care unit patients. J. Neurol. 268, 1323–1329 (2021).Article
CAS
PubMed
Google Scholar
Wihersaari, L. et al. Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Med. 47, 39–48 (2021).Article
PubMed
Google Scholar
Wihersaari, L. et al. Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. Resuscitation 174, 1–8 (2022).Article
CAS
PubMed
Google Scholar
Hunziker, S. et al. Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. Crit. Care 25, 32 (2021).Article
PubMed
PubMed Central
Google Scholar
Andersson, P. et al. Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. Crit. Care 25, 83 (2021).Article
PubMed
PubMed Central
Google Scholar
Blennow Nordström, E. et al. Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. Brain Inj. 36, 800–809 (2022).Article
PubMed
Google Scholar
Pouplet, C. et al. The accuracy of various neuro-prognostication algorithms and the added value of neurofilament light chain dosage for patients resuscitated from shockable cardiac arrest: an ancillary analysis of the ISOCRATE study. Resuscitation 171, 1–7 (2022).Article
PubMed
Google Scholar
Levin, H. et al. Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest. Crit. Care 27, 74 (2023).Article
PubMed
PubMed Central
Google Scholar
Adler, C. et al. Absolute serum neurofilament light chain levels and its early kinetics predict brain injury after out-of-hospital cardiac arrest. J. Neurol. 269, 1530–1537 (2022).Article
CAS
PubMed
Google Scholar
Kirschen, M. P. et al. Circulating neurofilament light chain is associated with survival after pediatric cardiac arrest*. Pediatr. Crit. Care Med. 21, 656–661 (2020).Article
PubMed
PubMed Central
Google Scholar
Fink, E. L. et al. Association of blood-based brain injury biomarker concentrations with outcomes after pediatric cardiac arrest. JAMA Netw. Open 5, e2230518 (2022).Article
PubMed
PubMed Central
Google Scholar
Hoiland, R. L. et al. Neurologic prognostication after cardiac arrest using brain biomarkers: a systematic review and meta-analysis. JAMA Neurol. 79, 390–398 (2022).Article
PubMed
PubMed Central
Google Scholar
Fu, Y. et al. Neuroprognostication value of serum neurofilament light chain for out-of-hospital cardiac arrest: a systematic review and meta-analysis. PLoS ONE 18, e0290619 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Ashton, N. J. et al. Alzheimer disease blood biomarkers in patients with out-of-hospital cardiac arrest. JAMA Neurol. 80, 388–396 (2023).Article
PubMed
PubMed Central
Google Scholar
Wang, S. L., Li, N., Feng, S. Y. & Li, Y. Serum neurofilament light chain as a predictive marker of neurologic outcome after cardiac arrest: a meta-analysis. BMC Cardiovasc. Disord. 23, 193 (2023).Article
PubMed
PubMed Central
Google Scholar
Nolan, J. P. et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med 47, 369–421 (2021).Article
PubMed
PubMed Central
Google Scholar
Panchal, A. R. et al. Part 3: adult basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 142, S366–S468 (2020).Article
PubMed
Google Scholar
Moseby-Knappe, M. et al. Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Med. 47, 984–994 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Lybeck, A. et al. Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. Resuscitation 158, 253–257 (2021).Article
PubMed
Google Scholar
Grindegård, L. et al. Association between EEG patterns and serum neurofilament light after cardiac arrest: a post hoc analysis of the TTM trial. Neurology 98, e2487–e2498 (2022).Article
PubMed
PubMed Central
Google Scholar
Lagebrant, A. et al. Brain injury markers in blood predict signs of hypoxic ischaemic encephalopathy on head computed tomography after cardiac arrest. Resuscitation 184, 109668 (2023).Article
PubMed
Google Scholar
Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 20, 385–397 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407–417 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Quadalti, C. et al. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Parkinsons Dis. 7, 93 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Holmberg, B., Rosengren, L., Karlsson, J. E. & Johnels, B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov. Disord. 13, 70–77 (1998).Article
CAS
PubMed
Google Scholar
Brettschneider, J. et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov. Disord. 21, 2224–2227 (2006).Article
PubMed
Google Scholar
Hall, S. et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445–1452 (2012).Article
PubMed
Google Scholar
Magdalinou, N. K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240–1247 (2015).Article
CAS
PubMed
Google Scholar
Mollenhauer, B. et al. Validation of serum neurofilament light chain as a biomarker of Parkinson’s disease progression. Mov. Disord. 35, 1999–2008 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Marques, T. M. et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92, e1479–e1486 (2019).Article
PubMed
Google Scholar
Peng, L. et al. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. J. Neurol. 270, 4248–4261 (2023).Article
PubMed
Google Scholar
Angelopoulou, E. et al. CSF and circulating NfL as biomarkers for the discrimination of Parkinson disease from atypical parkinsonian syndromes: meta-analysis. Neurol. Clin. Pract. 11, e867–e875 (2021).Article
PubMed
PubMed Central
Google Scholar
Martinez-Valbuena, I. et al. Combining skin α-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson’s disease. Mov. Disord. 37, 648–650 (2022).Article
CAS
PubMed
Google Scholar
Bäckström, D. et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 95, e827–e838 (2020).Article
PubMed
PubMed Central
Google Scholar
Rojas, J. C. et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90, e273–e281 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease. NPJ Parkinsons Dis. 8, 154 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Chelban, V. et al. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145, 4398–4408 (2022).Article
PubMed
PubMed Central
Google Scholar
Vijiaratnam, N. et al. Combining biomarkers for prognostic modelling of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 93, 707–715 (2022).Article
PubMed
Google Scholar
Ygland Rödström, E., Mattsson-Carlgren, N., Janelidze, S., Hansson, O. & Puschmann, A. Serum neurofilament light chain as a marker of progression in Parkinson’s disease: long-term observation and implications of clinical subtypes. J. Parkinsons Dis. 12, 571–584 (2022).Article
PubMed
PubMed Central
Google Scholar
Donker Kaat, L. et al. Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat. Disord. 56, 98–101 (2018).Article
PubMed
Google Scholar
Oosterveld, L. P. et al. CSF biomarkers reflecting protein pathology and axonal degeneration are associated with memory, attentional, and executive functioning in early-stage Parkinson’s disease. Int. J. Mol. Sci. 21, 8519 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Barba, L. et al. CSF synaptic biomarkers in AT(N)-based subgroups of Lewy body disease. Neurology 101, e50–e62 (2023).Article
CAS
PubMed
Google Scholar
Ye, R. et al. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: an 8-year longitudinal study. Parkinsonism Relat. Disord. 85, 11–16 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Yang, D. et al. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease. NPJ Parkinsons Dis. 9, 132 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Singer, W. et al. Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann. Neurol. 89, 1212–1220 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Park, D. G. et al. Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder. J. Neurol. 270, 4393–4402 (2023).Article
CAS
PubMed
Google Scholar
Zhang, X. et al. Neurofilament light protein predicts disease progression in idiopathic REM sleep behavior disorder. J. Parkinsons Dis. 13, 485–499 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 16, 601–609 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Byrne, L. M. et al. Neurofilament light protein as a potential blood biomarker for Huntington’s disease in children. Mov. Disord. 37, 1526–1531 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Gregory, S. et al. Characterizing white matter in Huntington’s disease. Mov. Disord. Clin. Pract. 7, 52–60 (2020).Article
PubMed
Google Scholar
Scahill, R. I. et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 19, 502–512 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Parkin, G. M., Corey-Bloom, J., Snell, C., Castleton, J. & Thomas, E. A. Plasma neurofilament light in Huntington’s disease: a marker for disease onset, but not symptom progression. Parkinsonism Relat. Disord. 87, 32–38 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Parkin, G. M. et al. Associations between prognostic index scores and plasma neurofilament light in Huntington’s disease. Parkinsonism Relat. Disord. 97, 25–28 (2022).Article
PubMed
PubMed Central
Google Scholar
Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. Sci. Transl. Med. 10, eaat7108 (2018).Article
PubMed
Google Scholar
Rodrigues, F. B. et al. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease. Sci. Transl. Med. 12, eabc2888 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Feasby, T. E. et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 109, 1115–1126 (1986).Article
PubMed
Google Scholar
Petzold, A. et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology 67, 1071–1073 (2006).Article
CAS
PubMed
Google Scholar
Axelsson, M. et al. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study. Acta Neurol. Scand. 138, 143–150 (2018).Article
CAS
PubMed
Google Scholar
Petzold, A. et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. Muscle Nerve 40, 42–49 (2009).Article
CAS
PubMed
Google Scholar
Altmann, P. et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. J. Neuroinflammation 17, 86 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Körtvelyessy, P. et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré syndrome. Ann. Clin. Transl. Neurol. 7, 2213–2220 (2020).Article
PubMed
PubMed Central
Google Scholar
Martín-Aguilar, L. et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2020-323899 (2020).Article
PubMed
Google Scholar
Dujmovic, I., Lunn, M. P., Reilly, M. M. & Petzold, A. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome. Muscle Nerve 48, 132–134 (2013).Article
PubMed
Google Scholar
Jin, M. et al. Cerebrospinal fluid neurofilament light chain predicts short-term prognosis in pediatric Guillain-Barré syndrome. Front. Neurol. 13, 972367 (2022).Article
PubMed
PubMed Central
Google Scholar
Sandelius, Å. et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90, e518–e524 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Bomont, P. et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat. Genet. 26, 370–374 (2000).Article
CAS
PubMed
Google Scholar
Mariotto, S. et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J. Peripher. Nerv. Syst. 23, 174–177 (2018).Article
CAS
PubMed
Google Scholar
van Lieverloo, G. G. A. et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 24, 187–194 (2019).Article
PubMed
Google Scholar
Karam, C. Chronic inflammatory demyelinating polyradiculoneuropathy: five new things. Neurol. Clin. Pract. 12, 258–262 (2022).Article
PubMed
PubMed Central
Google Scholar
Kapoor, M. et al. Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 29, 3347–3357 (2022).Article
PubMed
PubMed Central
Google Scholar
Kmezic, I. et al. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. Eur. J. Neurol. 29, 2810–2822 (2022).Article
PubMed
PubMed Central
Google Scholar
Kim, S.-H. et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci. Rep. 10, 7995 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Huehnchen, P. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7, e154395 (2022).Article
PubMed
PubMed Central
Google Scholar
Bischof, A. et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann. Rheum. Dis. 77, 1093–1094 (2018).Article
CAS
PubMed
Google Scholar
Rossor, A. M. et al. A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease. J. Peripher. Nerv. Syst. 27, 50–57 (2022).Article
CAS
PubMed
Google Scholar
Millere, E. et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur. J. Neurol. 28, 974–981 (2021).Article
PubMed
Google Scholar
Rossor, A. M. et al. Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease. Muscle Nerve 53, 972–975 (2016).Article
CAS
PubMed
Google Scholar
Kapoor, M. et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J. Peripher. Nerv. Syst. 24, 314–319 (2019).Article
CAS
PubMed
Google Scholar
Ticau, S. et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96, e412–e422 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Maia, L. F. et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27, 97–102 (2020).Article
CAS
PubMed
Google Scholar
Carroll, A. S. et al. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice. Amyloid https://doi.org/10.1080/13506129.2024.2313218 (2024).Article
PubMed
Google Scholar
Faravelli, I. et al. Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients. J. Cell Mol. Med. 24, 3034–3039 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Kong, L. et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci. Transl. Med. 13, eabb6871 (2021).Article
PubMed
PubMed Central
Google Scholar
Darras, B. T. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6, 932–944 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Nitz, E. et al. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann. Clin. Transl. Neurol. 8, 2013–2024 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Jin, J. et al. Plasma neurofilament light chain in Chinese children with later-onset spinal muscular atrophy. Clin. Chem. Lab. Med. 60, e237–e239 (2022).Article
CAS
PubMed
Google Scholar
Reilly, A. et al. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy. Gene Ther. 29, 544–554 (2022).Article
CAS
PubMed
Google Scholar
Ru, Y. et al. Neurofilament light is a treatment-responsive biomarker in CLN2 disease. Ann. Clin. Transl. Neurol. 6, 2437–2447 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Wurster, C. D. et al. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther. Adv. Neurol. Disord. 12, 1756286419846058 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Finkel, R. S. et al. Scientific rationale for a higher dose of nusinersen. Ann. Clin. Transl. Neurol. 9, 819–829 (2022).Article
PubMed
PubMed Central
Google Scholar
De Wel, B., De Schaepdryver, M., Poesen, K. & Claeys, K. G. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months. Ann. Clin. Transl. Neurol. 9, 1241–1251 (2022).Article
PubMed
PubMed Central
Google Scholar
Wilke, C. et al. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol. Med. 12, e11803 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Peng, Y. et al. Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3. Neurology 95, e2977–e2987 (2020).Article
CAS
PubMed
Google Scholar
Peng, L. et al. Blood neurofilament light chain in genetic ataxia: a meta-analysis. Mov. Disord. 37, 171–181 (2022).Article
CAS
PubMed
Google Scholar
Oender, D. et al. Evolution of clinical outcome measures and biomarkers in sporadic adult-onset degenerative ataxia. Mov. Disord. 38, 654–664 (2023).Article
CAS
PubMed
Google Scholar
Agrawal, N. et al. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1. Genet. Med. 25, 100349 (2023).Article
CAS
PubMed
Google Scholar
Nass, R. D. et al. Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: an exploratory study. Seizure 85, 1–5 (2021).Article
PubMed
Google Scholar
Giovannini, G. et al. Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus. Epilepsia 63, e23–e29 (2022).Article
CAS
PubMed
Google Scholar
Ouédraogo, O. et al. Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy. Epilepsia 62, 176–189 (2021).Article
PubMed
Google Scholar
Nissen, M. S. et al. CSF-neurofilament light chain levels in NMDAR and LGI1 encephalitis: a national cohort study. Front. Immunol. 12, 719432 (2021).Article
CAS
PubMed
PubMed Central
Google Scholar
Lardeux, P. et al. Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis. J. Neurol. 269, 377–388 (2022).Article
CAS
PubMed
Google Scholar
Guasp, M. et al. Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis. Neurology 98, e1489–e1498 (2022).Article
CAS
PubMed
Google Scholar
Ziemssen, T. et al. Serum neurofilament light chain as a biomarker of brain injury in Wilson’s disease: clinical and neuroradiological correlations. Mov. Disord. 37, 1074–1079 (2022).Article
CAS
PubMed
Google Scholar
Hermann, P. et al. Plasma neurofilament light chain as a biomarker for fatal familial insomnia. Eur. J. Neurol. 29, 1841–1846 (2022).Article
PubMed
Google Scholar
Alagaratnam, J. et al. Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. J. Neurovirol. 28, 54–63 (2022).Article
CAS
PubMed
Google Scholar
Smeele, P. J. et al. Neurofilament light increases over time in severe COVID-19 and is associated with delirium. Brain Commun. 4, fcac195 (2022).Article
PubMed
PubMed Central
Google Scholar
Cooper, J. et al. Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019. Crit. Care Explor. 2, e0238 (2020).Article
PubMed
PubMed Central
Google Scholar
Masvekar, R. R. et al. Prognostic value of serum/plasma neurofilament light chain for COVID-19-associated mortality. Ann. Clin. Transl. Neurol. 9, 622–632 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Abdelhak, A. et al. Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis. J. Neurol. 270, 3315–3328 (2023).Article
CAS
PubMed
PubMed Central
Google Scholar
Syrjanen, J. A. et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 18, 1128–1140 (2022).Article
CAS
PubMed
Google Scholar
Bittner, S., Oh, J., Havrdová, E. K., Tintoré, M. & Zipp, F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 144, 2954–2963 (2021).Article
PubMed
PubMed Central
Google Scholar
UniProt. P07197 HFM_Human https://www.uniprot.org/uniprotkb/P07197/entry (2024).UniProt. P12036 NFH_Human https://www.uniprot.org/uniprotkb/P12036/entry (2024).UniProt. P07196. NFL_Human https://www.uniprot.org/uniprotkb/P07196/entry (2024).UniProt. Q16352. AINX_Human https://www.uniprot.org/uniprotkb/Q16352/entry (2024).UniProt. P41219. PERI_Human https://www.uniprot.org/uniprotkb/P41219/entry (2024).